Bristol-Myers Re-Offers No New Offer for ImClone (IMCL, BMY)

Health and Healthcare

Published: September 11, 2008 10:03 am

Bristol-Myers Squibb (NYSE: BMY) has sent a letter to Imclone Systems (NASDAQ: IMCL) in response to yesterday’s rejection of its buyout offer. It said it is disappointed that the $60.00 bid was passed up for a highly conditional higher offer subject to due diligence. Bristol’s offer is not subject to due diligence. Bristol-Myers also said it will not make any alterations to its exclusive marketing rights for ERBITUX and the related compounds (including IMC-11F8).

As the letter states….."Notwithstanding ImClone’s receipt of ahighly conditional preliminary proposal from another party, we continueto look forward to engaging directly with ImClone and its financial andlegal advisors to discuss the merits of our all-cash offer, which isnot subject to due diligence or financing, to acquire the approximately83% of ImClone that we do not already own."

In short, Bristol-Myers is trying to start flexing its muscles now thatImClone and Carl Icahn have started showing face cards. ImClone is down1.4% at $66.95 today. Technically, this is no more than step-3 of along series of steps in an Icahn merger game.

Jon C. Ogg
September 11, 2008

ALERT: Take This Retirement Quiz Now (Sponsored)

Take the quiz below to get matched with a financial advisor today.

Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.

Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future

Take the retirement quiz right here.